{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T08:08:28Z","timestamp":1790064508675,"version":"4.0.1"},"reference-count":33,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,10,4]],"date-time":"2020-10-04T00:00:00Z","timestamp":1601769600000},"content-version":"am","delay-in-days":369,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.annder.2019.04.021","type":"journal-article","created":{"date-parts":[[2019,5,20]],"date-time":"2019-05-20T17:20:16Z","timestamp":1558372816000},"page":"634-639","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Lymphome c\u00e9r\u00e9bral primitif apr\u00e8s immunoth\u00e9rapie d\u2019un m\u00e9lanome m\u00e9tastatique"],"prefix":"10.1016","volume":"146","author":[{"given":"M.","family":"Castel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Cotten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Deschamps-Huvier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.-H.","family":"Commin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Marguet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Jardin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.-B.","family":"Duval-Modeste","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Joly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.annder.2019.04.021_bib0170","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1200\/JOP.2015.009498","article-title":"Targeting programmed death 1\/programmed death ligand 1\u00a0in lymphoma: a game changer","volume":"12","author":"Younes","year":"2016","journal-title":"J Oncol Pract"},{"key":"10.1016\/j.annder.2019.04.021_bib0175","first-page":"58","article-title":"Signaling pathway and dysregulation of PD1\u00a0and its ligands in lymphoid malignancies","volume":"1865","author":"Xia","year":"2016","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.annder.2019.04.021_bib0180","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.annder.2019.04.021_bib0185","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.praneu.2011.12.005","article-title":"Lymphome c\u00e9r\u00e9bral primitif chez un sujet immunocomp\u00e9tent","volume":"3","author":"Houillier","year":"2012","journal-title":"Pratique Neurologique FMC"},{"key":"10.1016\/j.annder.2019.04.021_bib0190","doi-asserted-by":"crossref","first-page":"191","DOI":"10.2176\/nmc.cr.2016-0330","article-title":"Immunotherapy of nivolumab with dendritic cell vaccination is effective against intractable recurrent primary central nervous system lymphoma: a case report","volume":"57","author":"Furuse","year":"2017","journal-title":"Neurol Med Chir (Tokyo)"},{"key":"10.1016\/j.annder.2019.04.021_bib0195","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/nrclinonc.2015.187","article-title":"Novel immunotherapies in lymphoid malignancies","volume":"13","author":"Batlevi","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.annder.2019.04.021_bib0200","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S1470-2045(13)70587-4","article-title":"Anti-PD1\u00a0antibody: a new approach to treatment of lymphomas","volume":"15","author":"Bachy","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.annder.2019.04.021_bib0205","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1002\/hon.2408","article-title":"Immunotherapy in lymphoma","volume":"35","author":"Ansell","year":"2017","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.annder.2019.04.021_bib0210","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1002\/hon.2375","article-title":"PD1\u00a0and PDL1\u00a0expression in primary central nervous system diffuse large B-cell lymphoma are frequent and expression of PD1\u00a0predicts poor survival","volume":"35","author":"Four","year":"2017","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.annder.2019.04.021_bib0215","doi-asserted-by":"crossref","first-page":"42","DOI":"10.5414\/NP300698","article-title":"PD1 (CD279) and PD-L1 (CD274, B7H1) expression in primary central nervous system lymphomas (PCNSL)","volume":"33","author":"Berghoff","year":"2014","journal-title":"Clin Neuropathol"},{"key":"10.1016\/j.annder.2019.04.021_bib0220","doi-asserted-by":"crossref","first-page":"S160","DOI":"10.1016\/S0007-4551(16)30374-5","article-title":"Utilisation des inhibiteurs de PD-1\u00a0dans les h\u00e9mopathies lympho\u00efdes","volume":"103","author":"Bounaix","year":"2016","journal-title":"Bull Cancer"},{"key":"10.1016\/j.annder.2019.04.021_bib0225","doi-asserted-by":"crossref","first-page":"32","DOI":"10.21037\/sci.2017.03.04","article-title":"Immune checkpoint blockade for hematologic malignancies: a review","volume":"4","author":"Pianko","year":"2017","journal-title":"Stem Cell Investig"},{"key":"10.1016\/j.annder.2019.04.021_bib0230","doi-asserted-by":"crossref","first-page":"3071","DOI":"10.1182\/blood-2017-01-764209","article-title":"PD-1\u00a0blockade with nivolumab in relapsed\/refractory primary central nervous system and testicular lymphoma","volume":"129","author":"Nayak","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.annder.2019.04.021_bib0235","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/nrclinonc.2016.168","article-title":"PD-1-PD-L1\u00a0immune-checkpoint blockade in B-cell lymphomas","volume":"14","author":"Goodman","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.annder.2019.04.021_bib0240","doi-asserted-by":"crossref","first-page":"3733","DOI":"10.1200\/JCO.2016.67.3467","article-title":"Programmed death-1\u00a0blockade with pembrolizumab in patients with classical Hodgkin lymphoma after brentuximab vedotin failure","volume":"34","author":"Armand","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.annder.2019.04.021_bib0245","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/ejh.13072","article-title":"Nivolumab maintenance after salvage autologous stem cell transplantation results in long-term remission in multiple relapsed primary CNS lymphoma","volume":"101","author":"Terziev","year":"2018","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.annder.2019.04.021_bib0250","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1182\/blood-2017-07-740993","article-title":"PD-1\u00a0expression and clinical PD-1\u00a0blockade in B-cell lymphomas","volume":"131","author":"Xu-Monette","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.annder.2019.04.021_bib0255","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1200\/JCO.2015.65.9789","article-title":"Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a phase Ib study","volume":"34","author":"Lesokhin","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.annder.2019.04.021_bib0260","doi-asserted-by":"crossref","first-page":"7519","DOI":"10.1200\/JCO.2017.35.15_suppl.7519","article-title":"Response rates with pembrolizumab in combination with rituximab in patients with relapsed follicular lymphoma: interim results of an on open-label, phase II study","volume":"35","author":"Nastoupil","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.annder.2019.04.021_bib0265","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1182\/blood-2016-12-758383","article-title":"Safety and tolerability of pembrolizumab in patients with relapsed\/refractory primary mediastinal large B-cell lymphoma","volume":"130","author":"Zinzani","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.annder.2019.04.021_bib0270","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1002\/hon.2437_49","article-title":"Efficacy and safety of pembrolizumab in relapsed\/refractory primary mediastinal large B-cell lymphoma (rrPMBCL): interim analysis of the KEYNOTE-170\u00a0phase 2\u00a0trial","volume":"35","author":"Zinzani","year":"2017","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.annder.2019.04.021_bib0275","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1200\/JCO.2014.60.0379","article-title":"Toxicities of immunotherapy for the practitioner","volume":"33","author":"Weber","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.annder.2019.04.021_bib0280","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1093\/annonc\/mdw141","article-title":"Toxicities of the anti-PD-1\u00a0and anti-PD-L1\u00a0immune checkpoint antibodies","volume":"27","author":"Naidoo","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annder.2019.04.021_bib0285","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.ejca.2016.02.025","article-title":"Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1\u00a0therapy","volume":"60","author":"Hofmann","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.annder.2019.04.021_bib0290","doi-asserted-by":"crossref","first-page":"S365","DOI":"10.1016\/j.annder.2016.09.581","article-title":"Cancers secondaires sous immunoth\u00e9rapies dans un contexte de m\u00e9lanome m\u00e9tastatique","volume":"143","author":"Mateus","year":"2016","journal-title":"Ann Dermatol Venereol"},{"key":"10.1016\/j.annder.2019.04.021_bib0295","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/S0140-6736(73)93174-7","article-title":"Association of malignant melanoma and malignant lymphoma","volume":"302","author":"Tashima","year":"1973","journal-title":"Lancet"},{"key":"10.1016\/j.annder.2019.04.021_bib0300","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1093\/jnci\/djy052","article-title":"Mutual risks of cutaneous melanoma and specific lymphoid neoplasms: second cancer occurrence and survival","volume":"110","author":"Herr","year":"2018","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.annder.2019.04.021_bib0305","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1002\/1097-0142(20010215)91:4<874::AID-CNCR1076>3.0.CO;2-O","article-title":"Evidence for an association between cutaneous melanoma and non-Hodgkin lymphoma","volume":"91","author":"Goggins","year":"2001","journal-title":"Cancer"},{"key":"10.1016\/j.annder.2019.04.021_bib0310","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1093\/annonc\/mdi080","article-title":"An association between cutaneous melanoma and non-Hodgkin's lymphoma: pooled analysis of published data with a review","volume":"16","author":"Lens","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annder.2019.04.021_bib0315","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1038\/bjc.1996.642","article-title":"Non-Hodgkin's lymphomas, chronic lymphocytic leukaemias and skin cancers","volume":"74","author":"Levi","year":"1996","journal-title":"Br J Cancer"},{"key":"10.1016\/j.annder.2019.04.021_bib0320","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.jaad.2009.07.039","article-title":"Risk of second primary malignancies following cutaneous melanoma diagnosis: a population-based study","volume":"62","author":"Spanogle","year":"2010","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.annder.2019.04.021_bib0325","doi-asserted-by":"crossref","first-page":"4935","DOI":"10.1200\/JCO.2010.29.1112","article-title":"Second malignancy risks after non-Hodgkin's lymphoma and chronic lymphocytic leukemia: differences by lymphoma subtype","volume":"28","author":"Morton","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.annder.2019.04.021_bib0165","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/sj.bjc.6600692","article-title":"Evidence for an association between cutaneous malignant melanoma and lymphoid malignancy: a population-based retrospective cohort study in Scotland","volume":"88","author":"McKenna","year":"2003","journal-title":"Br J Cancer"}],"container-title":["Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0151963819301620?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0151963819301620?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T11:07:46Z","timestamp":1758971266000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0151963819301620"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":33,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["S0151963819301620"],"URL":"https:\/\/doi.org\/10.1016\/j.annder.2019.04.021","relation":{},"ISSN":["0151-9638"],"issn-type":[{"value":"0151-9638","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lymphome c\u00e9r\u00e9bral primitif apr\u00e8s immunoth\u00e9rapie d\u2019un m\u00e9lanome m\u00e9tastatique","name":"articletitle","label":"Article Title"},{"value":"Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annder.2019.04.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}